SCM
VIVO

Soleus Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Soleus Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-163,000
Closed -$3.14M – 91
2021
Q3 		$3.14M Buy
+163,000
New +$3.25M 0.49% 51

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Soleus Capital Management's VIVO Position: Q4 2021 in Review

Soleus Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2021, closing a stake of 163,000 shares — an estimated $3.14M sold.

Soleus Capital Management first reported a position in VIVO in Q3 2021 and held it in 1 quarter. The position peaked at $3.14M in Q3 2021. 180 funds tracked by Wall St. Rank hold VIVO as of Q4 2021.

  • Soleus Capital Management reported no remaining Meridian Bioscience Inc position as of Q4 2021 after selling out during the quarter.
  • Soleus Capital Management sold 163,000 Meridian Bioscience Inc shares in Q4 2021, an estimated $3.14M.
  • Soleus Capital Management first reported a position in Meridian Bioscience Inc in Q3 2021 and held it in 1 quarter.
  • Soleus Capital Management's Meridian Bioscience Inc position peaked at $3.14M in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2021.

Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.